MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) has announced the development of a language-agnostic AI speech model capable of detecting drug and alcohol intoxication across multiple languages. This advancement aims to provide scalable, non-invasive testing for industries that require high-volume safety screening, such as mining, aviation, construction, and law enforcement.
The AI prediction model leverages over 50 million data points to predict alcohol intoxication with notable accuracy using only the human voice. According to the company, the technology is being integrated into an enterprise platform that includes Edge-AI kiosks with bespoke hardware and software for detecting both drug and alcohol intoxication in various enterprise environments.
This development is significant for industries where safety is paramount. For instance, in mining and construction, where workers operate heavy machinery, or in aviation, where pilots must remain unimpaired, a rapid, non-invasive test could streamline safety protocols. Law enforcement agencies could also benefit from a tool that provides quick intoxication assessments without requiring a blood or breath sample.
The cross-language capability is particularly important for global operations, as it allows the technology to be deployed across diverse linguistic regions without retraining the model for each language. This could reduce barriers to adoption for multinational companies and government agencies.
MindBio Therapeutics is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company's focus on voice-based detection offers a potential alternative to traditional methods that are often invasive, time-consuming, or require specialized equipment.
The implications of this technology extend beyond workplace safety. It could also be used in rehabilitation settings to monitor sobriety, or in event security to screen attendees. However, the immediate impact is likely to be felt in high-risk industries where regular testing is mandated.
For more information on MindBio Therapeutics and its technology, visit the company's newsroom at https://ibn.fm/MBQIF. The full press release is available at https://ibn.fm/PfjuT.
